<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370874</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC-DFU-301</org_study_id>
    <nct_id>NCT03370874</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.</brief_title>
  <official_title>Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in&#xD;
      patients with Diabetic Foot Ulcer, compared to placebo therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental: ALLO-ASC-DFU, Placebo Comparator: Vehicle Sheet, Study type: Interventional,&#xD;
      Study design: Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center&#xD;
      Study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure</measure>
    <time_frame>During 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time taken to complete wound closure between the two groups</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure</measure>
    <time_frame>Follow up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups</measure>
    <time_frame>Follow up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change rates in wound size and depth compared to baseline between the two groups</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations</measure>
    <time_frame>Follow up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Sheet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hydrogel sheet without Allogenic mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-ASC-DFU</intervention_name>
    <description>Application of ALLO-ASC-DFU sheet to diabetic foot ulcer</description>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <other_name>Hydrogel sheet containing allogenic mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vehicle sheet</intervention_name>
    <description>Application of Vehicle sheet to diabetic foot ulcer</description>
    <arm_group_label>Vehicle Sheet</arm_group_label>
    <other_name>Hydrogel sheet without Allogenic mesenchymal stem cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is between 18 and 75 years of age.&#xD;
&#xD;
          2. Subject is diagnosed with Type I or Type II diabetics and has diabetic foot ulcers for&#xD;
             longer than 4 weeks at the screening visit.&#xD;
&#xD;
          3. Foot ulcer size is between 1 cm2 and 15 cm2&#xD;
&#xD;
          4. Ulcer graded I or II by Wagner grade, and extended to skin, tendon, and subcutaneous&#xD;
             tissue.&#xD;
&#xD;
          5. Free of necrotic debris at target ulcer&#xD;
&#xD;
          6. Around ulcer area blood circulation should be secured to meet one of below criteria;&#xD;
&#xD;
               -  Blood vessels around the ulcer detected by Doppler Test&#xD;
&#xD;
               -  0.7 &lt; Ankle Brachial Index(ABI) &lt; 1.3&#xD;
&#xD;
               -  Transcutaneous Oxygen Pressure, TcPO2 higher than 30 mmHg&#xD;
&#xD;
          7. Subject is able to give written informed consent prior to study start and to comply&#xD;
             with the study requirements during study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-diabetic pathophysiologic ulcer.&#xD;
&#xD;
          2. The ulcer has increased or decreased in size by 30% or more during one week after the&#xD;
             screening visit.&#xD;
&#xD;
          3. Subjects requiring intravenous (IV) antibiotics to treat infection.&#xD;
&#xD;
          4. Current evidence of infection including pus drainage from the wound site.&#xD;
&#xD;
          5. Subject has a glycated hemoglobin A1c (HbA1c) level of &gt; 15%&#xD;
&#xD;
          6. Subject's blood sugar is &gt; 450 mg/dl at postprandial.&#xD;
&#xD;
          7. Subjects with severe renal failure that cannot be managed by renal dialysis.&#xD;
&#xD;
          8. Subjects with severe hepatic deficiencies.&#xD;
&#xD;
          9. Subject is Human Immunodeficiency Virus (HIV) positive.&#xD;
&#xD;
         10. Subject who has allergic or hypersensitive reaction to bovine-derived proteins or&#xD;
             fibrin glue.&#xD;
&#xD;
         11. Subject who is pregnant or breast-feeding.&#xD;
&#xD;
         12. Subjects who are unwilling to use an &quot;effective&quot; method of contraception during the&#xD;
             study.&#xD;
&#xD;
         13. Subjects who have a clinically relevant history of alcohol or drugs abuse.&#xD;
&#xD;
         14. Subjects who are not able to understand the objective of this study or to comply with&#xD;
             the study requirements.&#xD;
&#xD;
         15. Subjects who are considered to have a significant disease which can impact the study&#xD;
             by investigator.&#xD;
&#xD;
         16. Subjects who are considered not suitable for the study by investigator.&#xD;
&#xD;
         17. Subjects who had had a history of surgery for malignant tumor within the last five&#xD;
             years (except carcinoma in situ).&#xD;
&#xD;
         18. Subjects who are currently or are enrolled in another clinical study within 60 days of&#xD;
             screening.&#xD;
&#xD;
         19. Subjects who have undergone wound treatments with growth factors, dermal substitutes,&#xD;
             or other biological therapies within the last 30 days.&#xD;
&#xD;
         20. Subjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or&#xD;
             cytotoxic agents with unstable dose prior to 4 weeks from screening.&#xD;
&#xD;
         21. Subjects not comply with off-loading procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Kyu Han, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki-Won Young, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eulji General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junpyo Hong, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donghyeok Shin, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junhyeong Kim, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kang Chan, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyungmin Hahn, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Changsik Park, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youngkoo Lee, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Kuro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

